Drugs in Context最新文献_第2页

Medicines policy, access and use in Mexico: a systematic literature review 2000–2022 墨西哥的药品政策、获取和使用：2000-2022 年系统文献综述

Drugs in Context Pub Date : 2024-02-12 DOI: 10.7573/dic.2023-7-3

Laura C Vargas López, David Chávez Gallegos, Dolly Marlene Blanco Borjas, Veronika J Wirtz

引用次数: 0

How to handle off-label prescriptions of rupatadine, a second-generation antihistamine and PAF antagonist: a review 如何处理第二代抗组胺药和 PAF 拮抗剂鲁帕他定的标签外处方：综述

Drugs in Context Pub Date : 2024-01-18 DOI: 10.7573/dic.2023-9-5

Iñaki Izquierdo, Laia Casas, Susana Cabrera, Alberto Fernandez

引用次数: 0

Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts 心力衰竭的脆弱期：优化治疗的机会之窗--墨西哥专家的声明

Drugs in Context Pub Date : 2024-01-16 DOI: 10.7573/dic.2023-8-1

José Antonio Magaña Serrano, José Angel Cigarroa López, Adolfo Chávez Mendoza, J. B. Ivey-Miranda, Genaro Hiram Mendoza Zavala, Luis Olmos Domínguez, Sergio Armando Chávez Leal, José Ernesto Pombo Bartelt, Eduardo Heberto Herrera-Garza, Gerardo Mercado Leal, Rodolfo Parra Michel, Luisa Fernanda Aguilera Mora, Patricia Lenny Nuriulu Escobar

{"title":"Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts","authors":"José Antonio Magaña Serrano, José Angel Cigarroa López, Adolfo Chávez Mendoza, J. B. Ivey-Miranda, Genaro Hiram Mendoza Zavala, Luis Olmos Domínguez, Sergio Armando Chávez Leal, José Ernesto Pombo Bartelt, Eduardo Heberto Herrera-Garza, Gerardo Mercado Leal, Rodolfo Parra Michel, Luisa Fernanda Aguilera Mora, Patricia Lenny Nuriulu Escobar","doi":"10.7573/dic.2023-8-1","DOIUrl":"https://doi.org/10.7573/dic.2023-8-1","url":null,"abstract":"Acute heart failure (HF) is associated with poor prognosis. After the acute event, there is a vulnerable period during which the patient has a marked risk of readmission or death. Therefore, early optimization of treatment is mandatory during the vulnerable period. The objective of this article is to provide recommendations to address the management of patients with HF during the vulnerable period from a practical point of view. A group of Mexican experts met to prepare a consensus document. The vulnerable period, with a duration of up to 6 months after the acute event – either hospitalization, visit to the emergency department or the outpatient clinic/day hospital – represents a real window of opportunity to improve outcomes for these patients. To best individualize the recommendations, the management strategies were divided into three periods (early, intermediate and late vulnerable period), including not only therapeutic options but also evaluation and education. Importantly, the recommendations are addressed to the entire cardiology team, including physicians and nurses, but also other specialists implicated in the management of these patients. In conclusion, this document represents an opportunity to improve the management of this population at high risk, with the aim of reducing the burden of HF.","PeriodicalId":502654,"journal":{"name":"Drugs in Context","volume":"55 14","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139527839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-dose amphotericin: yay or nay? A case series and literature review 大剂量两性霉素：行还是不行？系列病例和文献综述

Drugs in Context Pub Date : 2024-01-15 DOI: 10.7573/dic.2023-9-1

Kayla R. Stover, Taylor E Jordan, Jamie L Wagner, Katie E. Barber

{"title":"High-dose amphotericin: yay or nay? A case series and literature review","authors":"Kayla R. Stover, Taylor E Jordan, Jamie L Wagner, Katie E. Barber","doi":"10.7573/dic.2023-9-1","DOIUrl":"https://doi.org/10.7573/dic.2023-9-1","url":null,"abstract":"Invasive fungal infections pose significant morbidity and mortality risks, particularly those caused by moulds. Available antifungal classes are limited by toxicities and are increasingly susceptible to resistance, particularly amongst challenging fungal pathogens. The purpose of this case series and literature review was to characterize the use of a high-dose lipid formulation of amphotericin B. A case series is presented including patients who received high-dose lipid formulation amphotericin B (≥7.5 mg/kg/day) between June 2012 and August 2021. Additionally, a systematic literature review was conducted by searching the PubMed database for English-language studies involving individuals who received high-dose amphotericin B therapy (≥7.5 mg/kg) using lipid formulations. Nine patients were included in the case series, receiving an average of 8.9 ± 1.3 mg/kg liposomal amphotericin B over a mean of 11.0 ± 10.8 days predominantly for mould infections including Mucorales, aspergillosis and Fusarium. The patients were primarily cared for in intensive care units, with varying treatment histories and outcomes. A total of 11 studies (n=260 patients) met inclusion criteria for the literature review. Responses to high-dose liposomal amphotericin B ranged from 8% to 100%, often showing favourable outcomes. High doses of liposomal amphotericin B were well tolerated both in the case series and in published literature, with serum creatinine changes being the most commonly reported adverse event. However, multi-patient studies continue to report less than favourable (range 8–62%) response rates. High-dose liposomal amphotericin B, either alone or in combination with other antifungal agents, might be a viable strategy for managing invasive fungal infections when few treatment choices exist. This article is part of the Challenges and strategies in the management of invasive fungal infections Special Issue: https://www.drugsincontext.com/special_issues/challenges-and-strategies-in-the-management-of-invasive-fungal-infections","PeriodicalId":502654,"journal":{"name":"Drugs in Context","volume":"16 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139529576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review and expert opinion on MAFLD, oxidative stress and multifunctional management 关于 MAFLD、氧化应激和多功能管理的评论和专家意见

Drugs in Context Pub Date : 2024-01-10 DOI: 10.7573/dic.2023-9-3

Francesco Angelico, Diana Alcantara-Payawal, R. A. Rani, Norlaila Mustafa, N. Thongtang, R. Chaiteerakij, C. Bunchorntavakul, A. Sukonthasarn

{"title":"Review and expert opinion on MAFLD, oxidative stress and multifunctional management","authors":"Francesco Angelico, Diana Alcantara-Payawal, R. A. Rani, Norlaila Mustafa, N. Thongtang, R. Chaiteerakij, C. Bunchorntavakul, A. Sukonthasarn","doi":"10.7573/dic.2023-9-3","DOIUrl":"https://doi.org/10.7573/dic.2023-9-3","url":null,"abstract":"Metabolic-associated fatty-liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is the most widespread and emerging chronic liver disease worldwide, with increasing prevalence rates also in the Asia-Pacific region. The disease has a high socio-economic burden as it negatively impacts the finances and quality of life of individuals affected and has a major burden on healthcare systems. The most important pathological event in MAFLD aetiopathogenesis is oxidative stress, which leads to functional and structural abnormalities in the liver as well as being involved in the development of other concomitant cardiometabolic diseases. MAFLD is a rather complex multisystemic clinical condition involving liver damage and a wide spectrum of extrahepatic manifestations such as obesity, type 2 diabetes, metabolic syndrome and cardiovascular diseases. This complexity requires the cooperation of multiple experts to identify MAFLD at an early stage, treat associated comorbidities, and promptly refer the patient to the hepatologist when needed. This review summarizes the current knowledge about MAFLD and reports the opinion of a group of experts on the increasing prevalence and burden of the disease in the southeast Asia region, the current journey of patients with MAFLD in developing countries, the role of oxidative stress and antioxidant treatment, and the importance of a multi-disciplinary approach for early diagnosis and disease management. This article is part of the Current clinical use of silymarin in the treatment of toxic liver diseases: a case series Special Issue: https://www.drugsincontext.com/special_issues/ current-clinical-use-of-silymarin-in-the-treatment-of-toxic-liver-diseases-a-case-series","PeriodicalId":502654,"journal":{"name":"Drugs in Context","volume":"81 14","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139440461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0